Business Context and Reporting Period
Company: GE Healthcare Technologies Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Reporting Period: Second Quarter 2026 (Strategic Change Implementation)
The Company announced a strategic reorganization of its executive leadership and reportable segments effective in the second quarter of 2026. This change combines the former Imaging and Advanced Visualization Solutions businesses into a new operating segment named Advanced Imaging Solutions (AIS). The Company now operates under three reportable segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
Key Financial Metrics
This filing provides recast unaudited historical financial information to reflect the new segment structure but does not contain specific financial performance data for the current period.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide specific values for revenue, profit, cash flow, or margins.
- Debt and Liquidity: The filing text does not provide specific values for debt or liquidity positions.
- Segment Structure: The new AIS segment encompasses Radiology, Specialized Ultrasound, and Procedural Guidance.
Material Changes Versus Prior Period
The primary material change is the reclassification of operating segments to align with how the Chief Operating Decision Maker reviews the business.
- Segment Consolidation: The former "Imaging" business (Radiology) and "Advanced Visualization Solutions" (AVS) business (Specialized Ultrasound and Procedural Guidance) have been merged into the new AIS segment.
- Recast Data: Supplemental recast unaudited financial information is provided in Exhibit 99 to ensure comparability with future reporting periods. This recasting has no impact on previously reported financial statements.
Guidance, Outlook, and Management Commentary
Strategic Rationale: Management states the reorganization is designed to enhance execution, accelerate innovation, and create efficiencies across the business.
Segment Details:
- Advanced Imaging Solutions (AIS): Focuses on diagnostic, interventional, and digital imaging technologies. Key product lines include CT, MR, Molecular Imaging, Enterprise Imaging software, Women's Health, X-ray systems, CardioVascular/Interventional Solutions, Surgical Innovations, and Comprehensive Care Ultrasound.
- Pharmaceutical Diagnostics (PDx) & Patient Care Solutions (PCS): These segments continue to operate as described in the 2025 Annual Report on Form 10-K.
Risks and Contingencies: The filing notes that the information furnished pursuant to Item 7.01 and Exhibit 99 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to liabilities under that section, except as expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99 attached to this filing for the specific recast unaudited historical financial data reflecting the new segment structure.
- Verify the impact of the segment consolidation on future quarterly reporting comparability.
- Confirm that previously reported financial statements remain unchanged despite the recasting of historical data for presentation purposes.
- Monitor subsequent filings for updated guidance or financial results under the new AIS, PDx, and PCS segment framework.